

Talking to Patients

about Safety of the Janssen COVID-19 Vaccine

Effective April 23, 2021, CDC and FDA recommend use of the Janssen COVID-19 Vaccine (Johnson & Johnson) resume in the United States.

The available data show that the vaccine's known and potential benefits outweigh its known and potential risks.

You can offer the Janssen COVID-19 Vaccine to people 18 years and older who want to get vaccinated against COVID-19.

As a clinician, your answers to patient questions matter. Your strong recommendation can help them make an informed decision and feel confident about getting vaccinated against COVID-19.

If your patient has questions about the safety of the Janssen COVID-19 Vaccine:

- ➔ Discuss the possibility of a **rare but increased risk** of blood clots with low platelets seen after receipt of the Janssen COVID-19 Vaccine.
- ➔ To date, most of these reports have been in adult women younger than 50 years old, but there have been reports in men and older women.
- ➔ The reporting rate for this event in women 18 to 49 years old is about 7 per 1 million women vaccinated, so this event is rare.
- ➔ The reporting rate for both women 50 years and older and men is less than 1 per 1 million people vaccinated.



I STRONGLY ENCOURAGE YOU TO GET VACCINATED.



- » Explain that there are other COVID-19 vaccine options available for which this specific risk has not been seen.
- » Consider and discuss if the patient will be able and willing to complete a two-dose mRNA vaccine series.
- » CDC and FDA will continue to monitor the safety of all COVID-19 vaccines.

If they have questions, you can send them to:

<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/JJUupdate.html>



[cdc.gov/coronavirus](https://www.cdc.gov/coronavirus)